Evidence map›Paper›PMID 27412129›Full record

ReviewParasites & vectors2016

New "light" for one-world approach toward safe and effective control of animal diseases and insect vectors from leishmaniac perspectives.

Kwang Poo Chang, Bala K Kolli, New Light Group

Open access · goldAbstract readReview
In one paragraph

Review in Parasites & vectors, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Progress in the photodynamic therapy treatment of Leishmaniasis.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021
    Review
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Kwang Poo ChangDepartment of Microbiology/Immunology, Chicago Medical School/Rosalind Franklin University of Medicine and Science, 3333 Green Bay Rd, North Chicago, IL, 60064, USA. kwangpoo.chang@rosalindfranklin.edu.ORCID 0000-0002-1317-1218
Bala K KolliDepartment of Microbiology/Immunology, Chicago Medical School/Rosalind Franklin University of Medicine and Science, 3333 Green Bay Rd, North Chicago, IL, 60064, USA.
New Light Group
Rosalind Franklin University of Medicine and Science · US

Funding

Photo-inactivation of Leishmania for safe and effective delivery of surrogate vacR21AI097830 · NIAID · ROSALIND FRANKLIN UNIV OF MEDICINE & SCI · PI CHANG, KWANG POO · 2012 to 2013
$413k
Transgenic porphyric Leishmania as suicidal live vaccines against leishmaniasisR21AI068835 · NIAID · ROSALIND FRANKLIN UNIV OF MEDICINE & SCI · PI CHANG, KWANG-POO · 2006 to 2007
$412k
NIAID NIH HHS R21 AI068835NIAID NIH HHS R21 AI097830
6 · The paper itself

Abstract

Light is known to excite photosensitizers (PS) to produce cytotoxic reactive oxygen species (ROS) in the presence of oxygen. This modality is attractive for designing control measures against animal diseases and pests. Many PS have a proven safety record. Also, the ROS cytotoxicity selects no resistant mutants, unlike other drugs and pesticides. Photodynamic therapy (PDT) refers to the use of PS as light activable tumoricides, microbicides and pesticides in medicine and agriculture.Here we describe "photodynamic vaccination" (PDV) that uses PDT-inactivation of parasites, i.e. Leishmania as whole-cell vaccines against leishmaniasis, and as a universal carrier to deliver transgenic add-on vaccines against other infectious and malignant diseases. The efficacy of Leishmania for vaccine delivery makes use of their inherent attributes to parasitize antigen (vaccine)-presenting cells. Inactivation of Leishmania by PDT provides safety for their use. This is accomplished in two different ways: (i) chemical engineering of PS to enhance their uptake, e.g. Si-phthalocyanines; and (ii) transgenic approach to render Leishmania inducible for porphyrinogenesis. Three different schemes of Leishmania-based PDV are presented diagrammatically to depict the cellular events resulting in cell-mediated immunity, as seen experimentally against leishmaniasis and Leishmania-delivered antigen in vitro and in vivo. Safety versus efficacy evaluations are under way for PDT-inactivated Leishmania, including those further processed to facilitate their storage and transport. Leishmania transfected to express cancer and viral vaccine candidates are being prepared accordingly for experimental trials.We have begun to examine PS-mediated photodynamic insecticides (PDI). Mosquito cells take up rose bengal/cyanosine, rendering them light-sensitive to undergo disintegration in vitro, thereby providing a cellular basis for the larvicidal activity seen by the same treatments. Ineffectiveness of phthalocyanines and porphyrins for PDI underscores its requirement for different PS. Differential uptake of PS by insect versus other cells to account for this difference is under study.The ongoing work is patterned after the one-world approach by enlisting the participation of experts in medicinal chemistry, cell/molecular biology, immunology, parasitology, entomology, cancer research, tropical medicine and veterinary medicine. The availability of multidisciplinary expertise is indispensable for implementation of the necessary studies to move the project toward product development.

Indexed as

Drug CarriersAnimalsCell SurvivalInsecticidesLeishmaniaMosquito ControlPhotosensitizing AgentsProtozoan VaccinesVaccinationDrug CarriersInsecticidesPhotosensitizing AgentsProtozoan VaccinesLeishmaniaMosquitoPhotodynamic insecticidePhotodynamic therapyPhotodynamic vaccinationPhotosensitizers

Identifiers

PMID27412129
PMCPMC4942964
OpenAlexW2468237633

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.